Uterine Cancer

When cancer first appears in the uterus it is called uterine cancer, it is more common after menopause and is considered the most common of the female reproductive organs. Conventional treatment options are surgery, radiotherapy, chemotherapy and hormone therapy and survival prospects are good when detected early.

LifEscozul™ - Uterine Cancer

On the other hand, cervical cancer was in the past one of the most common causes of death from cancer in women, until early detection through the Papanicolaou test has managed to reduce mortality by more than 50%. This cancer is more frequent in middle-aged women, and the main recognized cause is the incidence of human papillomavirus. Survival rates for cervical cancer exceed 90% when detected in early stages.

Treatment options offered by conventional medicine range from surgery, radiation therapy, brachytherapy, chemotherapy, targeted therapy on cancer-specific genes and proteins. The treatment options and effectiveness for patients with advanced cancer are aimed more than anything else at keeping the disease under control for as long as possible and relieving symptoms.

Escozu|™ can be administered in conjunction with any conventional treatment. Escozul™ seeks to work not only on the cancer but also on the patient|s quality of life. Its analgesic and anti-inflammatory effects help to improve the quality of life in about 65 to 75% of the patients treated. Through its antitumor effect, depending on the stage, one of the following results is expected: to slow down the disease progression, to stop tumor growth, to reduce the size of lesions or to eliminate tumor lesions.

It is important to point out that Escozu|™ is not considered a cure for cancer, it is a natural medicine that converts this deadly disease into a controlled chronic one, offering also quality of life.

Results in different cases

Advanced metastatic uterine cancer. Patient: Olivia Age: 47 years old.

Patient with a history of operated uterine cancer, with metastasis in multiple abomino-pelvic locations.

Olivia is a young patient, 47 years old, operated on in 2009 for uterine cancer. She came to us in March 2016, after several relapses of the disease, at a very advanced stage, with metastases in multiple locations. After one year of treatment, she is stable.

Case summary:

The case we share today is about a 47-year-old female patient who came to us at the end of March 2016, with a diagnosis of uterine cancer operated 7 years ago, with a first lymph node relapse in 2014. At the time she contacted us, she presented multiple tumor lesions in retroperitoneum, infiltration of numerous blood vessels, left kidney and bones.

When we received the medical documentation we were able to ascertain that it was a primary endometrial cancer (specifically a moderately differentiated endometrial adenocarcinoma), which after 7 years of surgery had metastasized to the peritoneum with involvement of the lower pole of the left kidney, infiltration of renal sinus with renal artery and vein, proximal third of ureter, perirenal fat, left psoas and square lumbar, with destruction of L3 vertebral body, infiltration of perivertebral tissue, and involving aorta, anterior vena cava and iliac arteries in its origin.

Regarding symptoms, he informed us that he presented lumbar pain, left leg and groin pain on the left side and difficulty sleeping.

Once the case had been analyzed by our specialists, we informed the patient about what to expect with Escozul™ and the possibilities of achieving good results, explaining the case in view of the prospect of an advanced disease.

Each dose of Escozul™ is personalized, specific to the type of tumor and its aggressiveness. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

Olivia started treatment with Escozul™ at the beginning of April 2016. She was pending to start chemotherapy and radiotherapy.

Evolution, Follow-up and Current Results:

During the time of treatment Olivia's condition was gradually improving, as well as her control tests. Finally the last examination received dated April 2017, one year after starting treatment, reveals that the bone metastases have disappeared, there is no involvement in the kidneys or nearby vessels, and the retroperitoneal tumor remains stable as well as the bone lesion at L3.

The results obtained in Olivia's case, with the combined use of Escozul™, chemotherapy and radiotherapy, have been very good, since we have managed to reduce and control the disease, giving Olivia a better life expectancy and a better quality of life, despite the initial situation which was not very encouraging.

We continue the treatment with Escozul™ with the intention of maintaining the results obtained and that Olivia can enjoy many more years of life with her family.

As we always say, it is important to point out that it is not possible to generalize any results with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, i.e. it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group May/2017

Medical Documents

LifEscozul™ - Olivia 1 - Cáncer de Útero y Cervix
LifEscozul™ - Olivia 2 - Cáncer de Útero y Cervix
LifEscozul™ - Olivia 3 - Cáncer de Útero y Cervix

Metastatic invasive cervical cancer. Patient: Irma Age: 66 years old.

Patient with a history of operated invasive cervical cancer, with metastasis to lung, liver and lymph nodes in multiple locations.

Irma is a 66 year old patient, operated on in 2010 for invasive cervical cancer. She came to us in March 2016, with multiple metastases, seeking other treatment options to improve her prospects for outcome and survival. After one year of treatment she has successfully cleared the disease.

Case summary:

The case we share today is about a 66-year-old female patient who came to us in March 2016, with a diagnosis of operated cervical cancer, with secondary tumor lesions in lung, liver, and cervical, thoracic and abdominal nodes.

When we received the medical documentation we were able to ascertain that it was a primary cancer of the cervix (specifically an epidermoid carcinoma), which after 6 years of surgery had metastasized to the liver, lung and lymph nodes in multiple cervical, thoracic and abdominal locations. The patient's condition according to her treating physicians was of rapid physical deterioration, with a poor evolution perspective.

As for symptoms, she informed us that she presented abdominal pain that made it difficult to eat and rest, abdominal swelling, loss of appetite, digestive problems, and she was depressed.

Once the case had been analyzed by our specialists, we informed the patient and her relatives about what they could expect with Escozu|™ and the possibilities of achieving good results, explaining the case in view of the prospect of an aggressive disease.

Each dose of Escozul™ is personalized, specific to the type of tumor and its aggressiveness. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozu|™ will not be as expected.

Irma started treatment with Escozul™ at the beginning of April 2016. She was undergoing chemotherapy.

Evolution, Follow-up and Current Results:

From the first studies we received from Irma, the results were very positive with a steady regression of the disease, evidenced by each new CT scan.

Regarding symptoms, by October 2016, 6 months into treatment, and despite chemotherapy, Irma's family members told us that she was in excellent physical condition, with no apparent symptoms of the disease, and leading a normal life.

In the CT scan of November 2016, lesions in the liver were no longer visible and the regression of the pulmonary nodules and lymph node involvement continued.

The last CT scan of April 2017, one year after starting treatment with Escozul™, shows a total regression of the disease.

The results obtained in Irma's case, with the joint use of Escozul™ and chemotherapy, have been very good, as we have been able to eliminate the disease, giving Irma a better life expectancy and better quality of life, as we have also achieved total regression of the symptoms.

We are continuing the treatment with Escozul™ with the intention of maintaining the results obtained and that Irma can enjoy many more years of life together with her family.

As we always say, it is important to point out that it is not possible to generalize any results with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, so it is not a commercial product.

properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, that is, it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group May/2017

Medical Documents

LifEscozul™ - Irma 1 - Cáncer de Útero y Cervix
LifEscozul™ - Irma 2 - Cáncer de Útero y Cervix
LifEscozul™ - Irma 3 - Cáncer de Útero y Cervix
LifEscozul™ - Irma 4 - Cáncer de Útero y Cervix
LifEscozul™ - Irma 5 - Cáncer de Útero y Cervix
LifEscozul™ - Irma 6 - Cáncer de Útero y Cervix

Vaginal tumor Patient: Magdalena Age: 86 Country: Mexico.

Patient diagnosed with a vaginal tumor in treatment only with Escozul™, overcomes her life expectancy and manages to reduce tumor.

Case Summary:

Patient diagnosed with a vaginal tumor on treatment only with Escozul™ overcomes her life expectancy and manages to reduce tumor.

Initial Diagnosis:

In May 2014, she is detected vaginal tumor displacing the bladder floor (non-keratinizing epidermoid carcinoma metastatic in right inguinal node, Ca advanced bladder transitional cells), urinary tract obstruction. Doctors gave a 3 prognosis of 3 months to live in August 2014.

Patient's condition before starting treatment:

  • - Severe pain.
  • - Unable to get up.

Escozul™ treatments:

Started with Escozul™ at the end of June 2014, with a dose and concentration according and the type of cancer, degree of progression and general condition of the patient. The main objective was to achieve stabilization of the patient, improving her quality of life and survival time.

Escozul™ is a natural product that has the ability to eliminate tumor cells without being a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the work approach is performed seeking that the patient can live with his disease with the least possible affectation to his daily routine.

Evolution of the case:

After the first two weeks of treatment, the patient began to improve her mood and increase her appetite noticeably, referring only burning when urinating which is frequent in the patient's affectation. In July 2014, a new control is performed where we are informed that the patient is well, with more energy and much more animated. By September her improvement is maintained, the patient no longer feels pain, she is animated, eats well, walks and performs daily activities at home.

The patient continues with a good quality of life, and the ultrasound shows a reduction of the tumor. The dose has been increased again in order to maintain and improve the results obtained. In 9 months of treatment we have managed not only to stabilize the disease, but also to reduce the size of the tumor, improve quality of life and keep the patient in good spirits, with energy and doing her daily activities.

It is important to emphasize that the patient has only been treated with Escozul™ without the interference of other medical treatments. This does not mean that Escozul™ is a cure for cancer but an alternative capable of providing control over the disease and its containment. It should be noted that the information provided in this case is available for consultation.

Medical Documents

LifEscozul™ - Magdalena 1 - Cáncer de Útero y Cervix
LifEscozul™ - Magdalena 2 - Cáncer de Útero y Cervix
LifEscozul™ - Magdalena 3 - Cáncer de Útero y Cervix
LifEscozul™ - Magdalena 4 - Cáncer de Útero y Cervix
LifEscozul™ - Magdalena 5 - Cáncer de Útero y Cervix
LifEscozul™ - Magdalena 6 - Cáncer de Útero y Cervix
LifEscozul™ - Magdalena 7 - Cáncer de Útero y Cervix
LifEscozul™ - Magdalena 8 - Cáncer de Útero y Cervix

Uterine Cancer Patient: Elsa Age: 71 Country: Chile

Uterine cancer in regression after 7 months of treatment with Escozul™.

Case Summary:

Uterine cancer in regression after 7 months on treatment with Escozul™.

Initial Diagnosis:

Stage III. inoperable uterine cancer, with metastases in lungs, liver and peritoneum.

Patient's condition before starting treatment:

  1. Pain in pelvic region
  2. Loss of appetite
  3. Loss of weight

Treatments with Escozul™:

Started with Escozul™ at the end of June 2014, with a dose and concentration according to the type of cancer, degree of progression and general condition of the patient. The main objective was to achieve stabilization of the patient, improving her quality of life and survival time.

Escozul™ is a natural product that has the ability to eliminate tumor cells without being a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the focus of work is done looking for the patient to be able to live with his disease with as little affectation as possible to his daily routine.

Treatments received:

Started with Escozul™ in June 2014, with doses prescribed according to type of cancer and disease progression, in addition to the patient's symptomatology. One month later, palliative chemotherapy was started.

Escozul™ has the ability to kill cancer cells without affecting healthy cells, which leads to tumor growth control and even tumor shrinkage, in addition to helping to improve the patient's quality of life. In cases of pancreatic cancer we have good results in about 80% of treated patients. with good results being understood as slowing down the disease, stopping its growth or reducing or eliminating tumors.

Case evolution:

In October 2014, in contrasted CT of thorax, abdomen and pelvis, the liver, lungs and uterus lesions were stable and there was already regression of the peritoneal lesions, despite the chemo the patient had recovered appetite and weight.

Current Results:

In January 2015, the CT scan result of the chest, abdomen and pelvis reports the following:

  • - Presence of metastatic pulmonary nodules, in smaller number than previous exam.
  • - No lesions in the liver
  • - No peritoneal lesions are observed.
  • - No alterations are observed in the uterus.
  • - She has regained 10 kilograms of weight
  • - No pain

Uterine cancer is one of the cancers with the best results when treated with Escozul™. In this case, together with chemotherapy, it has been possible to eliminate not only the primary tumor in the uterus, but also the secondary lesions in the uterus and peritoneum. There are still nodules in the lung, but this undoubtedly represents a considerable improvement in the patient's state of health and in her prognosis and quality of life.

Currently the patient continues with Escozul™, seeking to combat the remaining lesions in the lungs.

Medical Documents

LifEscozul™ - Elsa 1 - Cáncer de Útero y Cervix
LifEscozul™ - Elsa 2 - Cáncer de Útero y Cervix
LifEscozul™ - Elsa 3 - Cáncer de Útero y Cervix
LifEscozul™ - Elsa 4 - Cáncer de Útero y Cervix
LifEscozul™ - Elsa 5 - Cáncer de Útero y Cervix
LifEscozul™ - Elsa 6 - Cáncer de Útero y Cervix
LifEscozul™ - Elsa 7 - Cáncer de Útero y Cervix

Recurrence of Cervical Uterine Cancer Patient: Emma Age: 84 Country: Mexico

Results of treatment with Escozul™ in a patient with advanced cervical uterine cancer.

Escozul™ treatments:

Started with Escozul™ at the end of June 2014, with a dose and concentration according to the type of cancer, degree of progression and general condition of the patient. The main objective was to achieve stabilization of the patient, improving her quality of life and survival time.

Escozul™ is a natural product that has the ability to eliminate tumor cells without being a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the work approach is performed seeking that the patient can live with his disease with the least possible affectation to his daily routine.

Case summary:

Results of treatment with Escozul™ in patient with advanced cervical uterine cancer.

Initial Diagnosis:

Symptoms:

  • - Depression
  • - Lack of appetite
  • - Pain due to peripheral neuropathy
  • - Greenish, foul-smelling vaginal discharge.

Treatments received:

She started treatment with Escozul™ at the end of September 2014, with a high dose according to her and condition and treatment possibilities. She is not receiving chemo or radiotherapy. The condition of the kidneys makes chemotherapy very risky; new application of radiotherapy is not recommended due to the changes occurred after its application the first time. Due to the extension of the disease, it is also not a candidate for surgery.

Escozul™ has the ability to kill cancer cells without affecting healthy cells, which leads to the control of tumor growth and even to the reduction of tumors, besides helping to improve the patient's quality of life. When the disease is very advanced, it is expected to be able to help slow or stop its progression and with this increase the patient's life expectancy.

Evolution of the case:

At one month of treatment the vaginal discharge and was clearer and with less odor. The pain in the legs caused by the neuropathy decreased.

Examination in December 2014 indicated that the bladder involvement was inflammatory and not tumor.

Current Results:

In February regarding symptoms it is referred that vaginal discharge has decreased a lot, the same her unpleasant odor, appetite has increased, and other skin affections have improved. The signs of depression have decreased. The tumor at the bladder level that was observed in the initial analysis is now presented as an inflammatory process.

Medical Documents

LifEscozul™ - Emma 1 - Cáncer de Útero y Cervix
LifEscozul™ - Emma 2 - Cáncer de Útero y Cervix
LifEscozul™ - Emma 3 - Cáncer de Útero y Cervix
LifEscozul™ - Emma 4 - Cáncer de Útero y Cervix
LifEscozul™ - Emma 5 - Cáncer de Útero y Cervix
LifEscozul™ - Emma 6 - Cáncer de Útero y Cervix
LifEscozul™ - Emma 7 - Cáncer de Útero y Cervix